New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareProstamax vs VIP

Prostamax vs VIP

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Prostamax
Immune SupportSleep Optimization
VIP
Summary
Prostamax is a tetrapeptide bioregulator (Lys-Glu-Asp-Pro) developed by Professor Vladimir Khavinson, tissue-specific for the prostate gland. It supports prostate epithelial cell function, promotes normalization of prostate tissue, and is studied for its potential in benign prostatic hyperplasia (BPH), prostatitis, and prostate anti-aging. It is one of the more widely used Khavinson bioregulators among men over 40.
VIP is a 28-amino acid neuropeptide with profound anti-inflammatory, vasodilatory, and immunomodulatory effects. It plays a critical role in gut motility, circadian rhythm, and immune tolerance. Used therapeutically for CIRS (Chronic Inflammatory Response Syndrome), MCAS, and inflammatory conditions.
Half-Life
Short (minutes); sustained gene-regulatory effects
~2 minutes in plasma (rapidly degraded by peptidases); intranasal delivery may extend local CNS effects
Admin Route
SubQ, Oral
Intranasal, SubQ, IV
Research
Typical Dose
10 mg per day
50 mcg (4 sprays of 12.5 mcg each)
Frequency
Daily for 10–30 days
4x daily
Key Benefits
  • Supports normalization of prostate tissue architecture
  • May reduce prostate enlargement associated with BPH
  • Anti-inflammatory effects on prostatic tissue
  • Reduces prostate cell apoptosis from oxidative stress
  • Potential support in chronic prostatitis
  • Anti-aging effects on prostate glandular tissue
  • Complementary to conventional BPH therapies
  • Potent anti-inflammatory for CIRS and mold illness
  • Improves pulmonary hypertension symptoms
  • Regulates gut motility and IBS symptoms
  • Modulates circadian rhythm and sleep quality
  • Reduces mast cell activation (MCAS)
  • Improves cognitive function in neuroinflammatory conditions
  • Vasodilatory — reduces vascular resistance
Side Effects
  • Generally well tolerated in available research
  • Mild injection site reactions
  • No significant adverse urological events reported at standard doses
  • Facial flushing (transient, intranasal)
  • Mild nausea
  • Headache at initiation
  • Hypotension at high doses
  • +1 more
Stacks With